This company has shut down. Effector Therapeutics is no longer operating — its last tracked round was a Post-IPO Equity in 2024.
Explore the Startup GraveyardEffector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
Effector Therapeutics has raised $15.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2024.
Effector Therapeutics's investors include AbbVie, U.S. Venture Partners, The Column Group, Abingworth, SR One.
Effector Therapeutics is headquartered in San Diego, United States.
Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
Effector Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Effector Therapeutics — Funding & Investors." VCBacked, January 25, 2024, https://www.vcbacked.co/company/effector-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). Effector Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/effector-therapeutics
{{cite web |title=Effector Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/effector-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated